AGIOS PHARMACEUTICALS INC (AGIO)
US00847X1046 - Common Stock
Taking everything into account, AGIO scores 4 out of 10 in our fundamental rating. AGIO was compared to 586 industry peers in the Biotechnology industry. While AGIO has a great health rating, there are worries on its profitability. AGIO is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
AGIO had negative earnings in the past year.
In the past year AGIO has reported a negative cash flow from operations.
In the past 5 years AGIO reported 4 times negative net income.
AGIO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
AGIO's Return On Assets of -41.50% is in line compared to the rest of the industry. AGIO outperforms 57.80% of its industry peers.
With a decent Return On Equity value of -47.40%, AGIO is doing good in the industry, outperforming 68.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.5% | ||
| ROE | -47.4% | ||
| ROIC | N/A |
ROA(3y)18.44%
ROA(5y)-5.85%
ROE(3y)19.91%
ROE(5y)-17.29%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AGIO's Gross Margin of 89.96% is amongst the best of the industry. AGIO outperforms 93.31% of its industry peers.
AGIO's Gross Margin has declined in the last couple of years.
AGIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 89.96% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-1.95%
2. Health
2.1 Basic Checks
AGIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AGIO has been increased compared to 1 year ago.
Compared to 5 years ago, AGIO has less shares outstanding
There is no outstanding debt for AGIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 8.57 indicates that AGIO is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 8.57, AGIO belongs to the best of the industry, outperforming 84.39% of the companies in the same industry.
There is no outstanding debt for AGIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.57 |
ROIC/WACCN/A
WACC9.08%
2.3 Liquidity
A Current Ratio of 12.84 indicates that AGIO has no problem at all paying its short term obligations.
AGIO has a better Current ratio (12.84) than 84.91% of its industry peers.
AGIO has a Quick Ratio of 12.39. This indicates that AGIO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 12.39, AGIO belongs to the top of the industry, outperforming 83.70% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 12.84 | ||
| Quick Ratio | 12.39 |
3. Growth
3.1 Past
AGIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -59.19%.
The Revenue has grown by 54.58% in the past year. This is a very strong growth!
Measured over the past years, AGIO shows a very negative growth in Revenue. The Revenue has been decreasing by -22.25% on average per year.
EPS 1Y (TTM)-59.19%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q1.36%
Revenue 1Y (TTM)54.58%
Revenue growth 3YN/A
Revenue growth 5Y-22.25%
Revenue growth Q2Q46%
3.2 Future
AGIO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.59% yearly.
The Revenue is expected to grow by 84.70% on average over the next years. This is a very strong growth
EPS Next Y6.61%
EPS Next 2Y2.62%
EPS Next 3Y8.65%
EPS Next 5Y16.59%
Revenue Next Year54.2%
Revenue Next 2Y102.76%
Revenue Next 3Y92.6%
Revenue Next 5Y84.7%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
AGIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AGIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.62%
EPS Next 3Y8.65%
5. Dividend
5.1 Amount
No dividends for AGIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AGIOS PHARMACEUTICALS INC
NASDAQ:AGIO (5/21/2024, 3:30:00 PM)
After market: 33.88 0 (0%)33.88
+0.69 (+2.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.92B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.5% | ||
| ROE | -47.4% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 89.96% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 12.84 | ||
| Quick Ratio | 12.39 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-59.19%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y6.61%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)54.58%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y